丁苯酞联合依达拉奉治疗急性脑梗死的临床疗效观察

目的观察丁苯酞联合依达拉奉治疗急性脑梗死的临床疗效。方法242例急性脑梗死患者,依据随机数字表法分为研究组与对照组,各121例。对照组采用依达拉奉治疗,研究组采用丁苯酞联合依达拉奉治疗。比较两组治疗前后血液指标、美国国立卫生研究院卒中量表(NIHSS)评分及日常生活能力评定量表评分(Barthel指数)、治疗效果及不良反应发生情况。结果治疗后,两组全血高切粘度、同型半胱氨酸(Hcy)、C反应蛋白(CRP)水平均低于本组治疗前,活化部分凝血活酶时间(APTT)长于本组治疗前,且研究组全血高切粘度、Hcy、CRP水平均低于对照组,APTT长于对照组,差异均有统计学意义(P<0.05)。治疗后,两组NIHSS评分均低于本组治疗前,Barthel指数均高于本组治疗前,且研究组NIHSS评分(10.52±1.96)分低于对照组的(15.17±3.05)分,Barthel指数(85.34±6.76)分高于对照组的(74.82±7.67)分,差异均有统计学意义(P<0.05)。研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组药物不良反应率比较,差异无统计学意义(P>0.05)。结论急性脑梗死患者运用丁苯酞联合依达拉奉治疗,可减少神经功能缺损,改善患者的生活能力,提升治疗疗效,减少药物不良反应,效果理想。

Clinical efficacy of butylphthalide combined with edaravone in patients with acute cerebral infarction

Objective To observe the clinical efficacy of butylphthalide combined with edaravone in patients with acute cerebral infarction.Methods A total of 242 patients with acute cerebral infarction were divided into research group and control group according to the random numerical table method,with 121 cases in each group.The control group was treated with edaravone,and the research group was treated with butylphthalide and edaravone.The blood indexes,National Institutes of Health stroke scale(NIHSS)scores and the Barthel index scores before and after treatment,therapeutic effects and occurrence of adverse reactions were compared between the two groups.Results After treatment,the whole blood high shear viscosity,homocysteine(Hcy)and C-reactive protein(CRP)levels of the two groups were lower than those of this group before treatment,and the activated partial thromboplastin time(APTT)was longer than that of this group before treatment;the whole blood high shear viscosity,Hcy,and CRP levels of the research group were lower than those of the control group,and APTT was longer than that of the control group;all the differences were statistically significant(P<0.05).After treatment,the NIHSS scores of the two groups were lower than those of this group before treatment,and the Barthel index was higher than that of this group before treatment;the NIHSS score(10.52±1.96)points of the research group was lower than(15.17±3.05)points of the control group,and the Barthel index(85.34±6.76)points was higher than the control group(74.82±7.67)points;all the differences were statistically significant(P<0.05).The total effective rate of treatment in the research group was higher than that in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion The combination of butylphthalide and edaravone has ideal effect in the treatment of acute cerebral infarction,which can reduce the neurological defect,improve the living ability of the patients,improve the therapeutic effect and reduce the adverse drug reactions.